Recently, the fourth generation of CARs carrying a transgenic “payload”' such as IL-2 or IL-15 has been engineered to improve CAR-NK cell proliferation, longevity, and cytotoxicity against antigen-negative tumor cells. This evidence concerns the gene IL2 and neoplasm.